Browse recruiting and upcoming clinical trials for autoimmune encephalitis.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults (18–75) with relapsed/refractory antibody-mediated neurological autoimmune diseases such as MS, NMOSD, AE, CIDP, MG, MOGAD, or IIM.
What is being studied AITests safety, tolerability, and pharmacodynamics of QH103 (CD19 CAR-γδT) cell injection after lymphodepletion.
Who can join AIPeople with relapsing or refractory multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis.
What is being studied AITests safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy of RD06-05 (CD19/BCMA CAR‑T).
Who can join AIPeople aged 12 and older with anti‑N‑Methyl‑D‑Aspartate receptor (anti‑NMDAR) autoimmune encephalitis who have had first‑line immunotherapy.
What is being studied AICompares ofatumumab alone, ofatumumab plus daratumumab, and repeated IVIG/plasma exchange.
Who can join AIAdults 18–75 with relapsed/refractory antibody-mediated inflammatory diseases of the nervous system (eg, NMOSD, MG, CIDP, IIM, MS, AE, MOGAD, POEMS).
What is being studied AITests safety and effects of CT103A (BCMA-targeting CAR‑T) cells in relapsed/refractory antibody-mediated nervous system diseases.
Who can join AIAdults with Progressive Multiple Sclerosis, Neuromyelitis Optica, MOG antibody‑associated disease, autoimmune encephalitis, or Stiff‑Person Syndrome.
What is being studied AITests the safety and preliminary efficacy of CTX112, an anti‑CD19 allogeneic CAR‑T cell therapy.
Who can join AIPeople with Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, or Stiff Person Syndrome.
What is being studied AITests a single IV infusion of autologous CD20/BCMA-directed CAR-T cells (C-CAR168).
Who can join AIAdults 18–80 with certain dysfunctional brain disorders (cognitive, movement, disorders of consciousness, autoimmune encephalitis) and some normal volunteers.
What is being studied AIUses 18F‑DPA‑714 PET/MR to compare brain tracer uptake in patients and controls.
Who can join AIChildren aged 1–18 years with a first demyelinating event (ADEM, optic neuritis/NORB, or myelitis), with or without anti‑MOG antibodies.
What is being studied AICollects blood to study immune cell RNA and find biomarkers linked to relapsing ADEM/MOGAD.
Who can join AIWomen aged 20–55 with NMOSD, multiple sclerosis, autoimmune encephalitis, myasthenia gravis, Guillain‑Barré syndrome, or MOGAD planning pregnancy — and age‑matched healthy women planning pregnancy.
What is being studied AICollects clinical, imaging, and laboratory data before, during, and after pregnancy in women with neuroimmune diseases.
Who can join AIAdults with antibody-positive or seronegative autoimmune encephalitis or Susac syndrome, and neurological control patients without neuronal antibodies.
What is being studied AICollects clinical samples and uses single-cell and conventional methods to find and study autoantibodies.
Who can join AIPeople of any age with autoimmune encephalitis defined by anti‑NMDAR, anti‑LGI1, anti‑CASPR2, anti‑IgLON5, anti‑GAD65, or anti‑GFAP antibodies.
What is being studied AICollects treatment start data and clinical response at baseline and four months after therapy begins.
Who can join AIPeople newly diagnosed with autoimmune encephalitis or paraneoplastic neurological syndrome (per Graus criteria; excludes peripheral nervous system syndromes).
What is being studied AICollects clinical data, samples, and imaging to find biomarkers linked to prognosis across autoimmune encephalitis subtypes.
Who can join AIPeople diagnosed before age 18 with pediatric-onset inflammatory brain diseases, including MS, ADEM, MOGAD, NMOSD, anti‑NMDAR and other autoimmune encephalitides, optic neuritis, and transverse myelitis.
What is being studied AICollects clinical, diagnostic, treatment, and outcome data on pediatric inflammatory brain diseases for research and monitoring.
Who can join AIPeople aged 2 years and older with many neuroinflammatory, autoimmune, post‑infectious, GI, psychiatric or related conditions — and healthy controls.
What is being studied AICollects long-term health, symptom, and wearable data via an app to build a research data registry.
Who can join AIAdults 18–80 with a diagnosed neurological autoimmune disorder: MS, NMOSD, autoimmune encephalitis, MOGAD, autoimmune nodopathy, AIDP/CIDP, myasthenia gravis, or idiopathic inflammatory myopathy.
What is being studied AICollects clinical data, exam scores, antibodies, immune markers, and long-term outcomes.
Trials that may include autoimmune encephalitis (2)
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.